IPM Take
Medicine often treats breastfeeding as a background detail until a crisis forces it into the clinical conversation. In severe neuroimmune disease, that is not good enough.
The first report of MOG-IgG detected in human breast milk after severe MOGAD does not prove transmission risk, and it should not frighten mothers into simplistic decisions. Its value is different: it shows how little evidence exists when maternal neurology, immunotherapy, breastfeeding and infant safety intersect.
A mother should not have to choose between neurological urgency and infant care with only guesswork to guide her.
Executive Summary
A case report published in Neurology: Neuroimmunology & Neuroinflammation described detection of myelin oligodendrocyte glycoprotein antibodies, or MOG-IgG, in the breast milk of a lactating woman with severe MOG antibody-associated disease after enterovirus infection.
The patient was a 38-year-old breastfeeding woman who developed severe neurological disease requiring intensive care, including coma and nonconvulsive status epilepticus. Serum and cerebrospinal-fluid testing were strongly positive for MOG-IgG. Before immunotherapy, breast milk also tested positive for MOG-IgG at a lower titre.
The infant’s serum, tested later, was negative for MOG-IgG. The authors concluded that MOG-IgG may be detectable in breast milk but was probably not transmitted to the infant in detectable quantities in this case.
This is a single case report. It does not establish general breastfeeding risk in MOGAD and should support individualised counselling rather than broad recommendations.
Why it matters
- Patients / advocates: Mothers with neuroimmune disease need counselling that respects breastfeeding, infant safety and urgent maternal treatment needs.
- Clinicians: Severe MOGAD can require aggressive immunotherapy, and lactation questions should be addressed explicitly rather than improvised during crisis.
- Researchers / academia: The case highlights a major evidence gap in maternal neuroimmunology, antibody transfer and breastfeeding guidance.
A severe neuroimmune attack does not pause the rest of a woman’s life. It arrives into a real household, with an infant, feeding decisions, fear, treatment urgency and questions that clinicians may not be fully prepared to answer.
That is what makes this MOGAD case report important. The finding itself is narrow: MOG-IgG was detected in breast milk in one woman with severe disease, while the infant’s serum was later negative. It should not be turned into a general warning against breastfeeding, and it does not prove clinically meaningful antibody transfer to infants.
The broader problem is the absence of strong guidance when maternal neurological disease intersects with lactation. A woman who needs steroids, plasma exchange or other immunotherapy should not receive vague reassurance on one side and unnecessary alarm on the other. She needs an explanation of what is known, what is uncertain and how decisions will be made for her health and her child’s safety.
This is where patient-centred neuroimmunology has to become more practical. Pregnancy and breastfeeding cannot remain special situations handled through case-by-case improvisation after the emergency has already arrived. They need registries, systematic reporting, counselling tools and collaboration between neurology, obstetrics, paediatrics and lactation specialists.
For IPM, the story is not that one case changes practice. The story is that one case exposes how thin the evidence still is for mothers whose neurological disease does not fit neatly into standard care pathways.
